Flavivirus Cross-priming Potential of IMOJEV

Summary

There is a pressing need for a better experimental system to understand flavivirus antibody responses, beyond dengue, to make sure the investigators are using current vaccines to greatest effect and to inform the development of next-generation vaccines. This study will use live chimeric JE vaccine IMOJEV® as a tool for flavivirus epitope discovery. This will allow experimental JEV infection using replication competent, live, attenuated virus as a model, in a setting where the flavivirus infection history of humans can be tightly controlled.

Timeline

Start

2021-04-16

Primary completion

2021-12-23

Completion

2022-05-11

Drugs

Indications